Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

One of the most significant insights from the study is that roboticists must engage both technically and physically with ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

Neuroscientists have been trying to understand how the human brain supports numerous advanced capabilities for centuries. The ...

The unpredictable, debilitating nature of a seizure can be frightening, for both the person experiencing it and anyone watching nearby. In that moment, control often slips away as muscles stiffen, ...

The most common type of primary brain tumor is meningioma', a tumor that occurs in the meninges surrounding the brain. Most are slow to grow and positive, but about 15 to 20% of them are more ...

Over the past two decades, many emerging markets and developing economies have been viewed as increasingly resilient to ...